Geron Corporation is an advanced-stage biopharmaceutical company specializing in the creation and market introduction of therapies for myeloid hematologic malignancies. Its principal drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical trials. This agent is designed to curb the rampant proliferation of malignant stem and progenitor cells in these blood cancers.